Crexont (IPX203) vs Levodopa-carbidopa intestinal gel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Crexont (IPX203)

Marketed by Amneal Pharmaceuticals and partners

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT03670953 · Phase 3 · completed

The study was randomized, quadruple-blind, double-dummy, and active-controlled, with 506 participants entering the randomized maintenance period and 495 contributing primary-endpoint data. The clinical primary endpoint was met: IPX203 produced a significantly greater improvement in daily “good on” time than immediate-release carbidopa-levodopa (p=0.0194).

Next expected readout: February 2027 · NCT07138560 (registry estimate)

Reported efficacy

Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): IPX203 - Double-Blind Maintenance — Baseline (Week 7): 11.67 hours/day (Standard Deviation 2.943); Change at Week 20/ET: -0.39 hours/day (Standard Deviation 2.706) vs IR CD-LD - Double -Blind Maintenance — Baseline (Week 7): 11.72 hours/day (Standard Deviation 2.759); Change at Week 20/ET: -0.97 hours/day (Standard Deviation 3.081) (met)

Result source: NCT03670953

Levodopa-carbidopa intestinal gel · Duopa

Marketed by AbbVie

Approved in Parkinson's Diseasesmall molecule
Weak signal

NCT00335153 · Phase 3 · completed

This was a 354-participant, open-label, single-group study with no randomization, blinding, or comparator arm. Its primary outcomes focused on safety and device complications, and there was no formal controlled primary efficacy comparison, so the reported secondary improvements do not establish treatment efficacy.

Reported efficacy

Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): LCIG + Placebo Capsules -4.04 hours (Standard Error 0.65) vs Placebo Gel + Levodopa-Carbidopa Capsules -2.14 hours (Standard Error 0.66) (met)

Result source: NCT00357994

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCrexont (IPX203)Levodopa-carbidopa intestinal gel
OFF time, change—Not reported-4.0 vs -2.1vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
2 other results
  • -4.0 vs -2.1 wk 12 · n 35 · Phase 3 · primary NCT00660387
  • -2.2 vs 0.2 wk 12 · n 25 · Phase 3 · secondary NCT02799381
ON time without troublesome dyskinesia, change—Not reported4.1 vs 2.2vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
1 other result
  • 3.1 vs -0.1 wk 12 · n 25 · Phase 3 · secondary NCT02799381
UPDRS Part III, change—Not reported-1.5 vs -2.9vs Levodopa-Carbidopa Capsuleswk 12 · n 36NCT00357994
2 other results
  • -4.9 vs -0.9 wk 12 · n 25 · Phase 3 · secondary NCT02799381
  • -1.5 vs -2.9 wk 12 · n 36 · Phase 3 · secondary NCT00660387
MDS-UPDRS Part II, change—Not reported—Not posted · NCT01960842

OFF time, change

Crexont (IPX203)
—Not reported
Levodopa-carbidopa intestinal gel
-4.0 vs -2.1vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
2 other results
  • -4.0 vs -2.1 wk 12 · n 35 · Phase 3 · primary NCT00660387
  • -2.2 vs 0.2 wk 12 · n 25 · Phase 3 · secondary NCT02799381

ON time without troublesome dyskinesia, change

Crexont (IPX203)
—Not reported
Levodopa-carbidopa intestinal gel
4.1 vs 2.2vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
1 other result
  • 3.1 vs -0.1 wk 12 · n 25 · Phase 3 · secondary NCT02799381

UPDRS Part III, change

Crexont (IPX203)
—Not reported
Levodopa-carbidopa intestinal gel
-1.5 vs -2.9vs Levodopa-Carbidopa Capsuleswk 12 · n 36NCT00357994
2 other results
  • -4.9 vs -0.9 wk 12 · n 25 · Phase 3 · secondary NCT02799381
  • -1.5 vs -2.9 wk 12 · n 36 · Phase 3 · secondary NCT00660387

MDS-UPDRS Part II, change

Crexont (IPX203)
—Not reported
Levodopa-carbidopa intestinal gel
—Not posted · NCT01960842
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Crexont (IPX203): 2 of 4 rows · Levodopa-carbidopa intestinal gel: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCrexont (IPX203)Levodopa-carbidopa intestinal gel
Dropout rate
—IPX203 - Dose Conversion
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
—IPX203 - Double-Blind Maintenance
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.5%a
NCT00335153 · Phase 3
show 13 more results
5.4%
NCT00357994 · Phase 3
43.2%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
27.3%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
33.3%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
15.6%
NCT02549092 · Phase 3 · registry result, not featured evidence
44.7%
NCT00660673 · Phase 3 · registry result, not featured evidence
10.7%
NCT02799381 · Phase 3 · registry result, not featured evidence
—
NCT01736176 · Phase 3 · registry result, not featured evidence
9.7%
NCT01960842 · Phase 3 · registry result, not featured evidence
—
NCT00360568 · Phase 3 · registry result, not featured evidence
5.4%
NCT00660387 · Phase 3 · registry result, not featured evidence
37.5%
NCT01479127 · Phase 2 · registry result, not featured evidence
—
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
Discontinued due to AEs
—IPX203 - Dose Conversion
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
—IPX203 - Double-Blind Maintenance
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.4%a
NCT00335153 · Phase 3
show 13 more results
2.7%
NCT00357994 · Phase 3
18.9%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
22.7%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
11.1%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
4.4%
NCT02549092 · Phase 3 · registry result, not featured evidence
32.1%
NCT00660673 · Phase 3 · registry result, not featured evidence
3.6%
NCT02799381 · Phase 3 · registry result, not featured evidence
—
NCT01736176 · Phase 3 · registry result, not featured evidence
3.2%
NCT01960842 · Phase 3 · registry result, not featured evidence
—
NCT00360568 · Phase 3 · registry result, not featured evidence
2.7%
NCT00660387 · Phase 3 · registry result, not featured evidence
—
NCT01479127 · Phase 2 · registry result, not featured evidence
—
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
Serious AEs
2%IPX203 - Dose Conversion
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
3.1%IPX203 - Double-Blind Maintenance
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
30.5%a
NCT00335153 · Phase 3
show 13 more results
13.5%
NCT00357994 · Phase 3
66.7%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
77.3%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
77.8%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
20.9%
NCT02549092 · Phase 3 · registry result, not featured evidence
60.7%
NCT00660673 · Phase 3 · registry result, not featured evidence
7.1%
NCT02799381 · Phase 3 · registry result, not featured evidence
20.5%
NCT01736176 · Phase 3 · registry result, not featured evidence
12.9%
NCT01960842 · Phase 3 · registry result, not featured evidence
22.6%
NCT00360568 · Phase 3 · registry result, not featured evidence
13.5%
NCT00660387 · Phase 3 · registry result, not featured evidence
16.7%
NCT01479127 · Phase 2 · registry result, not featured evidence
0%
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
Most frequent reported AEs
dyskinesia 6.8%
nausea 4.9%
dry mouth 4.2%
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
nausea 4.3%
anxiety 2.7%
dizziness 2.3%
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
a
complication of device insertion 28.8%
abdominal pain 26%
insomnia 18.9%
NCT00335153 · Phase 3
show 13 more results
complication of device insertion 54.1%
abdominal pain 51.4%
nausea 29.7%
NCT00357994 · Phase 3
constipation 22.2%
depression 19.4%
device dislocation 19.4%
NCT00141518 · Phase 4 · registry result, not featured evidence
device dislocation 36.4%
excessive granulation tissue 31.8%
device related infection 27.3%
NCT00141518 · Phase 4 · registry result, not featured evidence
blood homocysteine increased 33.3%
device dislocation 27.8%
constipation 22.2%
NCT00141518 · Phase 4 · registry result, not featured evidence
stoma site pain 14%
abdominal pain 11.6%
stoma site infection 11.6%
NCT02549092 · Phase 3 · registry result, not featured evidence
vitamin b6 decreased 27.1%
blood homocysteine increased 22.5%
postoperative wound infection 21%
NCT00660673 · Phase 3 · registry result, not featured evidence
fall 21.4%
procedural pain 10.7%
abdominal pain 7.1%
NCT02799381 · Phase 3 · registry result, not featured evidence
procedural pain 33.3%
stoma site infection 28.2%
stoma site pain 23.1%
NCT01736176 · Phase 3 · registry result, not featured evidence
incision site pain 41.9%
excessive granulation tissue 32.3%
constipation 19.4%
NCT01960842 · Phase 3 · registry result, not featured evidence
incision site erythema 29%
fall 21%
vitamin b6 decreased 21%
NCT00360568 · Phase 3 · registry result, not featured evidence
complication of device insertion 54.1%
abdominal pain 51.4%
nausea 29.7%
NCT00660387 · Phase 3 · registry result, not featured evidence
dyskinesia 33.3%
fall 33.3%
anaemia 16.7%
NCT01479127 · Phase 2 · registry result, not featured evidence
cold sweat 9.1%
diarrhoea 9.1%
headache 9.1%
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1

Notes

  1. aPopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Crexont (IPX203)

Good on" Time -0.39 vs -0.97 IR CD-LD per day @ 20wk
absolute change · per day
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF-time 0.29 vs 0.76 IR CD-LD per day @ 20wk
absolute change · per day
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
PGI-C 29.7% (n=256) vs 18.8% (n=250) IR CD-LD @ 20wk
responder rate · % of participants
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part III 1.1 vs 0.9 IR CD-LD score @ 20wk
absolute change · score
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part II III 2 vs 1.8 IR CD-LD score @ 20wk
absolute change · score
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

Levodopa-carbidopa intestinal gel

AIMS Total -1.7 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint; n=317
NCT00335153 · Phase 3
OFF Time -4.44 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-1.3 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
Daily on Time With Td -0.36 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-0.24 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
Daily on Time Without Td 3.86 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
1.54 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
CGI-I 2.1 score @ 54wk
absolute value · score
No placebo or comparator arm
CGI-I at Endpoint
NCT00335153 · Phase 3
UPDRS I 0 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS II -4.4 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS Part III -7.4 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
0.6 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
UPDRS -11.7 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS IV -3.5 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
PDQ-39 Summary Index -6.9 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-0.7 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
PDQ-39 Mobility -11.2 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-2.5 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence

+ 333 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Crexont (IPX203)'s landscape · Levodopa-carbidopa intestinal gel's landscape